Vanguard Group Inc. Has $275.62 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vanguard Group Inc. boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,258,963 shares of the biopharmaceutical company's stock after buying an additional 458,143 shares during the quarter. Vanguard Group Inc. owned approximately 9.79% of Amicus Therapeutics worth $275,619,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $55,000. Point72 Asset Management L.P. bought a new position in Amicus Therapeutics during the 3rd quarter worth $13,530,000. Point72 DIFC Ltd acquired a new stake in Amicus Therapeutics in the third quarter worth $704,000. Wellington Management Group LLP lifted its stake in Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after buying an additional 2,856,101 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Amicus Therapeutics during the third quarter valued at $405,000.

Amicus Therapeutics Price Performance

Shares of FOLD traded up $0.17 during midday trading on Wednesday, reaching $6.89. The stock had a trading volume of 9,531,645 shares, compared to its average volume of 2,579,784. The firm's 50 day moving average price is $8.84 and its 200-day moving average price is $9.71. The company has a market capitalization of $2.12 billion, a P/E ratio of -38.28, a P/E/G ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 52 week low of $6.21 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on FOLD. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.